Leveraging High-Throughput Experimentation to Drive Pharmaceutical Route Invention: A Four-Step Commercial Synthesis of Branebrutinib (BMS-986195)-Reference-Cited by-同舟云学术

Leveraging High-Throughput Experimentation to Drive Pharmaceutical Route Invention: A Four-Step Commercial Synthesis of Branebrutinib (BMS-986195)

Published:2022-02-15 Issue:4 Volume:26 Page:1174-1183
ISSN:1083-6160
Container-title:Organic Process Research & Development
language:en
Short-container-title:Org. Process Res. Dev.

Author:

Stevens Jason M.¹^ORCID,Simmons Eric M.²^ORCID,Tan Yichen²,Borovika Alina²,Fan Junying²,Forest Robert V.²,Geng Peng²,Guerrero Carlos A.³,Lou Sha²^ORCID,Skliar Dimitri²,Steinhardt Sarah E.²,Strotman Neil A.⁴^ORCID

Affiliation:

1. Chemical Process Development, Bristol Myers Squibb, 556 Morris Ave, Summit, New Jersey 07901, United States

2. Chemical Process Development, Bristol Myers Squibb, 1 Squibb Drive, New Brunswick, New Jersey 08901, United States

3. Discovery Process Research, Janssen Research and Development, 1400 McKean Road, Spring House, Pennsylvania 19477, United States

4. Process Research and Development, Merck & Co., Inc., 126 E. Lincoln Ave, Rahway, New Jersey 07065, United States

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Physical and Theoretical Chemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.oprd.1c00443

Reference19 articles.

1. Genes on the X chromosome affect development of collagen-induced arthritis in mice

2. Ability of the xid gene to prevent autoimmunity in (NZB X NZW)F1 mice during the course of their natural history, after polyclonal stimulation, or following immunization with DNA.

3. Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton’s Tyrosine Kinase (BTK)

4. Bruton's tyrosine kinase inhibitor BMS-986142 in experimental models of rheumatoid arthritis enhances efficacy of agents representing clinical standard-of-care

5. Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton’s Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked Atropisomers

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HTE OS: A High-Throughput Experimentation Workflow Built from the Ground Up;Organic Process Research & Development;2024-06-27

2. Identifying general reaction conditions by bandit optimization;Nature;2024-02-28

3. Automation, analytics and artificial intelligence for chemical synthesis;Nature Synthesis;2023-05-30

4. Temperature-Controlled Photoreactors and ChemBeads as Key Technologies for Robust and Practical Photochemical HTE;Organic Process Research & Development;2023-04-13

5. A Brief Introduction to Chemical Reaction Optimization;Chemical Reviews;2023-02-23